NTX ND01
Alternative Names: NTX-ND01Latest Information Update: 16 Nov 2023
Price :
$50 *
At a glance
- Originator noctuRNA Therapeutics
- Class Circular RNA
- Mechanism of Action RNA degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Muscular dystrophies; Neurodegenerative disorders
Most Recent Events
- 15 Nov 2023 NoctuRNA Therapeutics has patent protection for RNA-based drug platform in an undisclosed location (noctuRNA Therapeutics website, November 2023)
- 15 Nov 2023 Preclinical trials in Muscular dystrophies in Spain (Parenteral) prior to November 2023 (noctuRNA Therapeutics pipeline, November 2023)
- 15 Nov 2023 Preclinical trials in Neurodegenerative disorders in Spain (Parenteral) prior to November 2023 (noctuRNA Therapeutics pipeline, November 2023)